Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrödinger, Inc. (Nasdaq: SDGR) is a computational science company focused on transforming molecular discovery for drug development and materials design. Its news flow reflects activity across software, collaborations, financial performance and a growing therapeutics portfolio, giving investors and industry observers insight into how its physics+AI platform is being applied in practice.
Recent press releases highlight progress in advancing Schrödinger’s physics+AI computational platform, including a predictive toxicology initiative, an AI-powered conversational interface in its Maestro graphical environment, and integration of Lilly’s TuneLab platform into LiveDesign, its cloud-native enterprise informatics environment. These updates illustrate how the company combines physics-based simulations with AI and machine learning to address challenges such as data scarcity in drug discovery.
Schrödinger’s news also covers collaborations and co-founded companies. Examples include expanded research agreements with Ajax Therapeutics, Lilly and Otsuka Pharmaceutical, as well as developments from Nimbus, Structure Therapeutics and Copernic Catalysts, all of which use Schrödinger’s platform in different ways. News items have described positive data for molecules such as zasocitinib, co-invented by Schrödinger and Nimbus, and the creation of a new ammonia synthesis catalyst in collaboration with Copernic.
On the corporate side, SDGR news includes quarterly financial results, updated financial guidance, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Pipeline updates for proprietary programs such as SGR-1505, SGR-3515, SGR-5573 and SGR-6016 appear alongside platform and partnership announcements, providing a combined view of software and drug discovery activities.
Investors and researchers can use the SDGR news page to follow earnings releases, platform enhancements, regulatory designations, collaborative milestones and governance disclosures that shape the company’s trajectory.
Schrödinger, Inc. (Nasdaq: SDGR) has announced a strategic two-year collaboration with The University of Texas MD Anderson Cancer Center to advance its WEE1 inhibitor program. The partnership aims to optimize therapeutic development through biomarker-driven patient stratification and clinical study prioritization. Schrödinger's WEE1 inhibitors showed promising preclinical results, and the collaboration will investigate their potential as single agents and in combination therapies for specific cancer types. Schrödinger retains sole responsibility for development and commercialization of these compounds.
Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options for 45,050 shares to 15 newly hired employees on
Schrödinger (Nasdaq: SDGR) has announced its participation in four investor conferences in September 2021. On September 9 at 2:00 p.m. ET, the company will present at the Morgan Stanley 19th Annual Global Healthcare Conference. A pre-recorded presentation will be available on September 13. Additionally, Schrödinger will participate in the BofA Global Healthcare Conference on September 16 and the BofA Securities Drug Discovery Conference on September 20. Live webcasts can be accessed on their website and will be archived for about seven days.
Schrödinger, Inc. (Nasdaq: SDGR) recently granted stock options to 13 new employees, totaling 25,150 shares under its 2021 Inducement Equity Incentive Plan. The options, priced at $57.40 per share, were approved by the compensation committee and are intended to attract talent. Each option has a 10-year term, vesting over four years. Schrödinger's innovative software platform advances drug development and material science, serving clients globally to accelerate the discovery of novel therapeutics.
Schrödinger (Nasdaq: SDGR) announced a 29% increase in Q2 2021 revenue to $29.8 million, with software revenue rising 15% to $24.1 million. The company reported a gross profit of $12 million, though overall operating expenses grew to $42.3 million, leading to a net loss of $34.6 million. Notably, Schrödinger has partnered with Zai Lab to co-develop an oncology program, and expects to submit up to three IND applications in 2022. The company anticipates full-year revenue between $124 million and $142 million. Cash and equivalents totaled $616.6 million as of June 30, 2021.
Schrödinger (Nasdaq: SDGR) and Zai Lab (Nasdaq: ZLAB; HKEX: 9688) have announced a collaboration to jointly discover, develop, and commercialize a novel oncology program targeting DNA damage response. Zai Lab will initially fund Schrödinger's research costs and lead global development post candidate selection. Schrödinger retains co-development rights in the U.S. and can earn up to $338 million in milestone payments, plus royalties on international sales. This partnership aims to leverage both companies' expertise to accelerate innovative cancer therapies.
Schrödinger (Nasdaq: SDGR) is set to host a conference call on August 12, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results and provide a business update. The event will be accessible via webcast on their investor site. Schrödinger is known for its innovative physics-based software platform that facilitates the rapid discovery of novel therapeutics and materials, significantly reducing costs compared to traditional methods. The company collaborates with various sectors globally, leveraging its technology to enhance drug development.
Schrödinger, Inc. (Nasdaq: SDGR) is hosting its first annual Educator's Day, aimed at enhancing the role of computational tools in education. The event features discussions on the development of curricula for teaching chemical interactions and drug design using Schrödinger's software. Keynote speaker Dr. Brent R. Stockwell emphasizes the importance of modern curricula for today’s scientists. Schrödinger aims to fill the resource gap in hands-on learning by training educators and facilitating effective learning through innovative methods.
Schrödinger (Nasdaq: SDGR) announced the granting of stock options to 14 new employees on July 15, 2021, totaling 32,975 shares. These options, part of the 2021 Inducement Equity Incentive Plan, have an exercise price of $67.46, matching the closing stock price on the grant date. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. This initiative aims to attract talent and is compliant with Nasdaq Listing Rule 5635(c)(4).
Schrödinger (Nasdaq: SDGR) is set to present at two investor conferences in July 2021. The first presentation will occur on July 20, 2021, at the Evercore ISI AI x Therapeutics Day at 1:30 PM ET. The second presentation is scheduled for July 28, 2021, at the SVB Leerink CybeRx Conference at 2:00 PM ET. Schrödinger's innovative physics-based software platform enhances the discovery of therapeutics and materials, allowing for faster and cost-effective development.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
